This paper provides an economic explanation for the non-existence of a vaccine against AIDS. It comments on previously claimed economic reasons why private laboratories do not have incentives to invest in an AIDS vaccine and provides a new one: private companies already operate in the market for treatment of already infected patients, which market is threatened by the eventual emergence of a vaccine that cuts the cycle of infection. Finally, the paper discusses some mechanisms to provide incentives for further private research in diseases where a treatment product already exists.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
Publisher Info
Article provided by World Economics, Economic & Financial Publishing, PO Box 69, Henley-on-Thames, Oxfordshire, United Kingdom, RG9 1GB in its journal World Economics Journal.
Volume (Year): 2 (2001) Issue (Month): 4 (October) Pages: 117-132 Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF
Handle: RePEc:wej:wldecn:84
Contact details of provider:
For technical questions regarding this item, or to correct its listing, contact: (Ed Jones).
Related research
Keywords:
Cited by: (explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)
Did you know? All full texts are decentralized with the publishers, none reside on this server, thus making it possible to offer this service for free to all parties.